Cytokinetics | CYTK - Current Assets


Cytokinetics reported $1.21B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Arca Biopharma USD 884.56M 489.31M Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Brainstorm Cell Therapeutics USD 316K 132K Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Capricor Therapeutics USD 242.13M 40.96M Jun/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Geron USD 486.34M 12.19M Jun/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026